Results 171 to 180 of about 428,009 (193)

Characterisation of People Living With Chronic Hepatitis B Virus Infection in England and Stratification by HBsAg Levels: A Cross-Sectional Study. [PDF]

J Viral Hepat
Drysdale M, Gillespie IA, Christensen D, Davies J, Woods K, Roadknight G, Little S, Salih H, Várnai KA, Noble T, Cooke GS, Glampson B, Papadimitriou D, Mayer E, Khakoo SI, Davis C, Borca F, English L, Nastouli E, Matthews PC, Barnes E, Wang T.   +21 more
europepmc   +1 more source

Relationship Between Nucleos(t)ide analogue antiviral response time and prognosis in Chronic Hepatitis B: conclusions depend on baseline viral load and HBeAg status. [PDF]

Front Pharmacol
Huang J, Li X, You L, Chong Y, Cao H.
europepmc   +1 more source

Safety and efficacy of PD-1 antibody combined with pegylated interferon α for functional cure in nucleos(t)ide analogues-suppressed chronic hepatitis B patients: protocol for a multicentre randomised controlled trial. [PDF]

BMJ Open
Wang H, Li X, Lu J, Zhang X, Dang S, Li Y, He Y, Guo Y, Wang J, Maimaitijiang W, Zheng S, Ren S, Cao H, Zhang W, Zhang X, Ma H, Wang FS, Fu J.   +17 more
europepmc   +1 more source

Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on "Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)ide analogues". [PDF]

Clin Mol Hepatol
Jang H, Kim W.
europepmc   +1 more source

A meta-analysis of controlled clinical trials comparing peginterferon-α plus nucleos(t)ide analogs versus peginterferon-α monotherapy for HBsAg clearance or seroconversion in patients with chronic hepatitis B. [PDF]

Front Med (Lausanne)
Zhu S, Yang Z, Wang Y, Cai X, Qin C.
europepmc   +1 more source